CortagenvsCrystagen

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide belonging to the Khavinson family of peptide bioregulators — short peptides proposed to regulate gene expression in a tissue-specific manner. The bioregulator hypothesis, developed by Professor Vladimir Khavinson over decades of research at the St. Petersburg Institute of Bioregulation and Gerontology, proposes that short peptides (2-4 amino acids) can penetrate cell membranes and nuclear envelopes, interact directly with DNA in a sequence-specific manner, and modulate transcription of tissue-relevant genes.

Cortagen is specifically designed to target neurons of the cerebral cortex. According to the Khavinson model, the AEDP tetrapeptide sequence has complementarity to specific DNA sequences in gene promoter regions active in cortical neurons. Upon binding to these regulatory elements, Cortagen is proposed to modulate chromatin structure and transcription factor access, influencing the expression of genes involved in neuronal function, synaptic transmission, antioxidant defense, and protein synthesis. The tissue specificity — cortex rather than other brain regions or body tissues — is attributed to the unique chromatin accessibility and transcription factor environment in cortical neurons that determines which genes are available for regulation.

Preclinical studies from Russian research programs have reported that Cortagen treatment improves cognitive function, enhances learning and memory, and provides neuroprotection in models of cerebral ischemia and age-related cognitive decline. The proposed mechanism involves restoration of age-related declines in protein synthesis in cortical neurons, enhancement of antioxidant enzyme expression (SOD, catalase, GPx), and improved synaptic function through upregulation of synaptophysin and other synaptic proteins. It should be noted that the peptide bioregulator field remains controversial in Western pharmacology — while the Russian research program is extensive, the proposed direct DNA-binding mechanism has not been independently validated through the standard molecular biology methods expected in Western peer-reviewed literature.

Crystagen is a short Khavinson tripeptide (Glu-Asp-Pro) positioned as the immune and thymus-targeted bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the standard family framework: short peptides interact with gene promoter sequences in thymic and lymphocyte cell nuclei, modulating expression of genes involved in T cell maturation, cytokine production, and broader immune regulation.

Proposed effects include support for thymic function — particularly relevant given the well-documented age-related thymic involution that contributes to immunosenescence in older adults — alongside modulation of lymphocyte chromatin organisation and immune cell maturation pathways. Russian research has reported crystagen-induced improvements in lymphocyte counts, T helper cell function, and clinical recovery from infections in elderly populations and in patients recovering from immunosuppressive treatments. The peptide is often used alongside thymalin (a related thymic peptide preparation also in this database) as part of broader Khavinson immune-support protocols.

As with the rest of the Khavinson family, the efficacy evidence base sits within Russian gerontology and immunology research with limited independent Western validation. Crystagen is not validated as a treatment for primary immunodeficiency, HIV-related immune dysfunction, or other formally diagnosed immune conditions, and should not displace evidence-based immune therapy. The brief plasma half-life (around 30 minutes) reflects the proposed model of transient signalling triggering longer-lasting transcriptional changes in immune cell populations.